Novartis signs mRNA deal for about $7.8 billion with China's Abogen

Chinese biotech company Abogen ​said on Friday it signed ‌a licensing deal worth about $7.8 billion with Swiss drug maker Novartis to ​advance RNA-based therapy.

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。